Compare Crispr Therapeutics AG (CRSP) vs iShares S&P GSCI Commodity-Indexed Trust ETF (GSG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs iShares S&P GSCI Commodity-Indexed Trust ETF — how do they compare? Crispr Therapeutics AG trades at $53.95 (market cap $5.23B), while iShares S&P GSCI Commodity-Indexed Trust ETF trades at $32.61. The key difference: iShares S&P GSCI Commodity-Indexed Trust ETF is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | GSG | |
|---|---|---|
Market Cap | $5.23B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $76.78 | $34.77 |
52-Week Low | $44.34 | $22.06 |
Enterprise Value | $3.65B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
GSG trades at $32.65, up 1.02% today, with a bearish technical signal driven by moving averages. Recent news highlights its energy-centric commodity exposure, which fueled strong H1 2026 performance but faces volatility risks. Financial ratios are unavailable, limiting fundamental clarity.
Outlook is cautious due to sector volatility and geopolitical risks, with a recent downgrade to Hold. Opportunities lie in broad commodity exposure, but investors should weigh energy price swings and lack of current financial data against potential gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About iShares S&P GSCI Commodity-Indexed Trust ETF
GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.
Read more on GSG →
